MedTrace Logo

Echothiophate Iodide for the Prevention of Progression of Myopia

NCT02544529 · Status: WITHDRAWN · Phase: PHASE4 · Type: INTERVENTIONAL

Last updated 2025-02-07

No results posted yet for this study

Summary

The purpose of this study is to test the hypothesis that myopia progression can be slowed or prevented by low dose Echothiophate Iodide.

Conditions

  • Myopia

Interventions

DRUG

Echothiophate Iodide 0.03% Ophthalmic Solution

one drop to each eye three times per week for 18 weeks

DRUG

Carboxymethylcellulose Sodium (0.5%)

one drop to each eye three times per week for 18 weeks

Sponsors & Collaborators

  • Danbury Eye Physicians & Surgeons, PC

    lead OTHER

Principal Investigators

  • Stephen A Mathias, MD, MPH · Danbury Eye Physicians & Surgeons, PC

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
SINGLE_GROUP

Eligibility

Min Age
9 Years
Max Age
15 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-06-01
Primary Completion
2016-06-01
Completion
2016-06-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02544529 on ClinicalTrials.gov